Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model J Gebert, O Gelincik, M Oezcan-Wahlbrink, JD Marshall, ... Gastroenterology, 2021 | 78 | 2021 |
Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum J Liu, CL Hsieh, O Gelincik, B Devolder, S Sei, S Zhang, SM Lipkin, ... Journal of proteomics 195, 125-137, 2019 | 61 | 2019 |
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa L Reyes-Uribe, W Wu, O Gelincik, PV Bommi, A Francisco-Cruz, LM Solis, ... Gut 70 (3), 555-566, 2021 | 45 | 2021 |
ETHE1 overexpression promotes SIRT1 and PGC1α mediated aerobic glycolysis, oxidative phosphorylation, mitochondrial biogenesis and colorectal cancer M Witherspoon, D Sandu, C Lu, K Wang, R Edwards, A Yeung, O Gelincik, ... Oncotarget 10 (40), 4004, 2019 | 21 | 2019 |
Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair S Jahid, J Sun, O Gelincik, P Blecua, W Edelmann, R Kucherlapati, ... Oncotarget 8 (42), 71574, 2017 | 8 | 2017 |
Abstract 2732: Frameshift neoantigen vaccination prevent Lynch syndrome mouse model intestinal cancer O Gelincik, H Ibrahim, M Ozkan, A Ahadova, S Sei, R Shoemaker, M Kloor, ... Cancer Research 79 (13 Supplement), 2732-2732, 2019 | 5 | 2019 |
Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model (vol 161, pg 1288, 2021) J Gebert, O Gelincik, M Oezcan-Wahlbrink Gastroenterology 161 (6), 2070-2070, 2021 | 2 | 2021 |
Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome Y Song, H Loomans-Kropp, RN Baugher, B Somerville, SS Baxter, ... JNCI: Journal of the National Cancer Institute 116 (6), 957-965, 2024 | | 2024 |
Abstract CT111: Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa LR Uribe, W Wu, O Gelincik, PV Bommi, A Francisco-Cruz, LM Solis, ... Cancer Research 80 (16 Supplement), CT111-CT111, 2020 | | 2020 |
Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum (vol 8, pg 125, 2019) J Liu, CL Hsieh, O Gelincik, B Devolder, S Sei, S Zhang, SM Lipkin, ... JOURNAL OF PROTEOMICS 200, 161-161, 2019 | | 2019 |
Immunoprevention of Lynch syndrome mouse model intestinal cancer with recurrent neoantigen vaccination Ö Gelincik, M Kloor, M Özcan, A Ahadova, Y Yuan, H Ibrahim, S Sei, ... | | 2019 |
Abstract 717: Mouse model for the development of preventive and therapeutic vaccines against microsatellite-unstable cancers M Kloor, M Oezcan, A Ahadova, Y Yuan, P Bork, S Sei, R Shoemaker, ... Cancer Research 78 (13 Supplement), 717-717, 2018 | | 2018 |